FDA Panel Backs Genzyme Corporation’s Mass-Produced Myozyme

SILVER SPRING, Md., Oct 21 (Reuters) - A mass-produced version of Genzyme Corp's drug to treat the fatal genetic disorder Pompe disease should be approved as long as further studies are required, a U.S. advisory panel said on Tuesday.